Bioxytran Inc Financials
This page shows Bioxytran Inc (BIXT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Persistent operating losses are being financed externally while liabilities remain far larger than reported assets.
In FY2025, current liabilities exceeded total assets—$3.25M versus$659K —leaving a current ratio of 0.2x and negative equity of-$2.59M . Operating cash flow of-$526K occurred alongside$1.05M of financing inflows, indicating that reported activity depended more on outside funding than internally generated cash.
The company reported an operating loss of
The reported liquidity comparison equals 11.6 months of the latest annual operating outflow, but the balance sheet still shows severe short-term imbalance because current assets were only
Some figures from recent filings were inconsistent and were omitted from this summary.
Financial Health Signals
Bioxytran Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Bioxytran Inc passes 2 of 5 computable financial strength tests (4 of the nine could not be computed from available data). 1 of 3 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
Bioxytran Inc reported a net loss of $2.1M while operations used $526K of cash. With neither figure positive, the ratio between the two carries no quality signal.
Bioxytran Inc reported an operating loss of $1.8M against $134K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Bioxytran Inc reported -$2.1M in net income in fiscal year 2025.
Bioxytran Inc earned -$0.02 per diluted share (EPS) in fiscal year 2025. That is unchanged from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Bioxytran Inc held $510K in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
None of these metrics is reported for fiscal year 2025.
Capital Allocation
Bioxytran Inc invested $454K in research and development in fiscal year 2025. This represents an increase of 304.1% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
BIXT Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $255K+13.3% | $225K | N/A | N/A | $103K-70.7% | $350K | N/A | $51K |
| SG&A Expenses | $189K-11.6% | $214K | N/A | $159K+68.3% | $95K-34.2% | $144K | N/A | $158K |
| Operating Income | -$655K+66.1% | -$1.9M | N/A | -$496K-121.4% | -$224K+56.5% | -$515K | N/A | -$346K |
| Interest Expense | $36K+1.1% | $36K | N/A | $37K+21.3% | $30K-3.4% | $31K | N/A | $18K |
| Net Income | -$620K+70.0% | -$2.1M | N/A | -$283K-897.8% | $35K | N/A | N/A | -$392K |
| EPS (Diluted) | -$0.01 | -$0.02 | $0.00 | $0.00 | $0.00+100.0% | -$0.02-100.0% | -$0.01 | $0.00 |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Income Tax.
BIXT Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $333K-45.8% | $615K-6.6% | $659K+321.4% | $156K+6.0% | $148K+8.4% | $136K-1.9% | $139K-12.8% | $159K |
| Current Assets | $177K-61.7% | $463K-9.8% | $513K+3441.4% | $14K+361.2% | $3K-27.7% | $4K-15.6% | $5K-85.1% | $35K |
| Cash & Equivalents | $177K-61.7% | $463K-9.2% | $510K+3416.9% | $14K+361.2% | $3K-27.7% | $4K-15.6% | $5K-85.1% | $35K |
| Total Liabilities | $5.3M+5.3% | $5.0M+54.2% | $3.2M+6.2% | $3.1M+10.0% | $2.8M-2.2% | $2.8M+47.3% | $1.9M+55.2% | $1.2M |
| Current Liabilities | $5.3M+5.3% | $5.0M+54.2% | $3.2M+6.2% | $3.1M+10.0% | $2.8M-2.2% | $2.8M+47.3% | $1.9M+55.2% | $1.2M |
| Total Equity | -$4.9M-12.4% | -$4.4M-69.6% | -$2.6M+10.8% | -$2.9M-10.2% | -$2.6M+2.7% | -$2.7M-51.1% | -$1.8M-65.2% | -$1.1M |
| Retained Earnings | -$23.7M-2.7% | -$23.1M-9.8% | -$21.0M-2.5% | -$20.5M-1.4% | -$20.2M+0.2% | -$20.3M-7.2% | -$18.9M-3.4% | -$18.3M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
BIXT Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$350K-46.6% | -$239K-0.7% | -$237K-384.0% | -$49K+33.1% | -$73K+56.3% | -$167K-30.8% | -$128K-74.0% | -$74K |
| Investing Cash Flow | -$9K-1.7% | -$9K-47.9% | -$6K-49.2% | -$4K+66.9% | -$13K-84253.3% | -$15+99.9% | -$12K-11.6% | -$11K |
| Financing Cash Flow | $73K-63.4% | $201K-72.8% | $739K+1045.1% | $65K-23.8% | $85K-49.2% | $167K+50.7% | $110K+4.7% | $106K |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
BIXT Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Return on Assets | -185.9%+150.3pp | -336.3% | N/A | -180.9%-204.9pp | 24.0% | N/A | N/A | -246.8% |
| Current Ratio | 0.03-0.1x | 0.09-0.1x | 0.16+0.2x | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.03 |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Debt-to-Equity, FCF Margin.
Note: Shareholder equity is negative (-$2.6M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.16), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Where Bioxytran Inc Ranks
Frequently Asked Questions
Is Bioxytran Inc profitable?
No, Bioxytran Inc (BIXT) reported a net income of -$2.1M in fiscal year 2025.
What is Bioxytran Inc's operating cash flow?
Bioxytran Inc (BIXT) recorded an outflow of $526K in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Bioxytran Inc's total assets?
Bioxytran Inc (BIXT) had $659K in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Bioxytran Inc spend on research and development?
Bioxytran Inc (BIXT) invested $454K in research and development during fiscal year 2025.
What is Bioxytran Inc's current ratio?
Bioxytran Inc (BIXT) had a current ratio of 0.16 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Bioxytran Inc's return on assets (ROA)?
Bioxytran Inc (BIXT) had a return on assets of -322.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does Bioxytran Inc's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Bioxytran Inc (BIXT) held $510K in cash, cash equivalents and investments, and reported an operating cash outflow of $526K over that year. Dividing the one by the other, the reported balance equals about 12 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Why is Bioxytran Inc's debt-to-equity ratio negative or not reported?
Bioxytran Inc (BIXT) has negative shareholder equity of -$2.6M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Bioxytran Inc's Piotroski F-Score?
Bioxytran Inc (BIXT) has a Piotroski F-Score of 2 out of 5 computable signals; 4 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Bioxytran Inc's earnings high quality?
Bioxytran Inc (BIXT) reported a net loss of $2.1M while operations used $526K of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Bioxytran Inc cover its interest payments?
Bioxytran Inc (BIXT) reported an operating loss of $1.8M against $134K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.